(Q55478814)

12 July 2018

meta-analysis

0 references

title

Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. (English)

1 reference

12 July 2018

0 references

Stuschke M

1

1 reference

12 July 2018

Thames HD

series ordinal

2

1 reference

12 July 2018

language of work or name

English

0 references

publication date

1 January 1997

1 reference

12 July 2018

International Journal of Radiation Oncology Biology Physics

published in

1 reference

12 July 2018

volume

37

1 reference

12 July 2018

page(s)

259-267

1 reference

12 July 2018

issue

2

1 reference

12 July 2018

Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer: influence of tumour proliferation

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Radiotherapy of the rhabdomyosarcoma R1H of the rat: hyperfractionation--126 fractions applied within 6 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Clinical radiobiology of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

A method for assessing the quality of a randomized control trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Irradiation therapy with multiple small fractions per day in urinary bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Misonidazole combined with hyperfractionation in the management of malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Effects of irradiation by single or multiple fractions per day on transplantable murine mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Kinetics of recovery from sublethal radiation damage in four murine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Response of human tumour xenografts to fractionated X-irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Onc

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Dose intensification in curative head and neck cancer radiotherapy--linear quadratic analysis and preliminary assessment of clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Malignant astrocytoma. Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Fractionation sensitivity (alpha/beta ratio) of human melanoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Fraction size in external beam radiation therapy in the treatment of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Superfractionation radiation therapy in the treatment of malignant astrocytoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Heterogeneity in the fractionation sensitivities of human tumor cell lines: studies in a three-dimensional model system

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Time-dose factors in radiotherapy: a review of the human data.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Characteristics of dose-response relationships for late radiation effects: an analysis of skin telangiectasia and of head and neck morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

1 reference

7 January 2021

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

The response of two human tumor xenografts to fractionated irradiation. The derivation of alpha/beta ratios from growth delay, tumor control, and in vitro cell survival assays

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2896%2900511-1

7 January 2021

10.1016/S0360-3016(96)00511-1

Identifiers

DOI

1 reference

12 July 2018

PubMed ID

9069295

1 reference

12 July 2018